Skip to main content
S&P 5007,605.41+0.26%DOW52,031.40-0.12%NASDAQ26,149.03+0.64%BTC$75,705.00-0.76%ETH$2,389.42-1.19%GOLD$4,387.70+1.27%OIL$102.69-2.97%
Smart Investors Daily
TM

NASDAQ · TMDX

TransMedics Group, Inc.

Healthcare · Medical - Devices

$88.09

Down-$0.70 (-0.79%)

Updated Sep 16, 2026, 5:07 PM

SID Score

4.4/10

Composite research score

Smart Money

58/100

Neutral

Market cap
4.37B
P/E ratio
47.56
Dividend yield
0.00%
52-week range
$60.11 – $135.28
Volume
942.86K
Avg. volume
933.82K

Price performance

TMDX price history

1M range · 20 trading sessions · Daily adjusted prices

TMDX closed at $88.09 after 20 trading sessions, down 2.87% for the selected period.

Last close
$88.09
Period change
-2.87%
Period low
$82.18
Period high
$94.77
Daily close
View OHLC price history
TMDX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$86.39$90.67$85.4703$88.09942.86K
Sep 14, 2026$82.615$88.49$80.585$85.86943.38K
Sep 11, 2026$85.36$86.00$79.23$82.181.25M
Sep 10, 2026$85.27$87.55$83.69$85.04591.86K
Sep 9, 2026$87.47$87.71$84.87$86.40665.16K
Sep 8, 2026$89.14$89.55$86.15$88.27594.55K
Sep 4, 2026$84.63$90.11$83.61$89.98542.8K
Sep 3, 2026$85.72$87.545$84.60$86.98574.88K
Sep 2, 2026$82.23$85.52$82.23$84.29589.84K
Sep 1, 2026$85.84$86.00$81.3401$82.24883.99K
Aug 31, 2026$87.645$88.00$82.55$84.871.19M
Aug 28, 2026$91.90$93.4499$88.37$88.43631.16K
Aug 27, 2026$91.59$94.24$91.13$91.75418.39K
Aug 26, 2026$92.26$93.1575$90.24$92.22448.87K
Aug 25, 2026$93.62$94.33$91.5005$93.60405.44K
Aug 24, 2026$94.07$94.52$92.04$93.60770.37K
Aug 21, 2026$91.11$95.18$90.445$94.77628.72K
Aug 20, 2026$92.88$94.30$90.635$90.85589.6K
Aug 19, 2026$90.15$94.99$90.15$93.97703.33K
Aug 18, 2026$88.45$92.50$88.45$90.69778.3K

Latest TMDX news

The latest Smart Investors Daily articles mentioning TMDX.

Stock researchCompany · Overview

TMDX research

Overview

Company profile and research snapshot.

Company profile

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$148.00
Implied upside
—
Analysts
20
TMDX recent ratings
DateFirmRatingTarget
Sep 8, 2026TD CowenBuy—
Aug 5, 2026Piper SandlerOverweight—
Aug 5, 2026UBSNeutral—
Aug 3, 2026NeedhamBuy—
Jul 28, 2026UBSNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 10, 2026

TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief Financial Officer, effective September 21, 2026. Mr. Araujo brings more than 20 years of public-company finance leadership at GE HealthCare, General Electric, and 3M to support the Company's next phase of global growth. He succeeds Gerardo Hernandez, who will transition to Commercial Strategic Adviso

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By